Evidence map›Paper›PMID 38223885›Full record

ArticleLiver research (Beijing, China)2023

Effects of Bacillus Calmette-Guérin on immunometabolism, microbiome and liver diseases

Muhammad Umair Ijaz, Farzam Vaziri, Yu-Jui Yvonne Wan

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Liver research (Beijing, China), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Muhammad Umair IjazDepartment of Medical Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
Farzam VaziriDepartment of Medical Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
Yu-Jui Yvonne WanDepartment of Medical Pathology and Laboratory Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
University of California Davis Medical Center · US

Funding

Liver Cancer Therapy by MiR-22 and Its InducersR01CA222490 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WAN, YU-JUI YVONNE · 2018 to 2023
$2.1M
NCI NIH HHS R01 CA222490
6 · The paper itself

Abstract

Metabolic diseases have overtaken infectious diseases as the most serious public health issue and economic burden in most countries. Moreover, metabolic diseases increase the risk of having infectious diseases. The treatment of metabolic disease may require a long-term strategy of taking multiple medications, which can be costly and have side effects. Attempts to expand the therapeutic use of vaccination to prevent or treat metabolic diseases have attracted significant interest. A growing body of evidence indicates that Bacillus Calmette-Guérin (BCG) offers protection against non-infectious diseases. The non-specific effects of BCG occur likely due to the induction of trained immunity. In this regard, understanding how BCG influences the development of chronic metabolic health including liver diseases would be important. This review focuses on research on BCG, the constellation of disorders associated with metabolic health issues including liver diseases and diabetes as well as how BCG affects the gut microbiome, immunity, and metabolism.

Indexed as

Bacillus Calmette-Guérin (BCG)DiabetesGut microbiotaLiver diseaseMetabolic diseasesTrained immunityVaccination

Identifiers

PMID38223885
PMCPMC10786626
OpenAlexW4377115695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.